Advances in understanding the potential therapeutic applications of gut microbiota and probiotic mediated therapies in celiac disease.
celiac disease
gastro-intestinal symptoms
gluten free diet
gut microbiota
irritable bowel syndrome.
probiotics
wheat deglutination
Journal
Expert review of gastroenterology & hepatology
ISSN: 1747-4132
Titre abrégé: Expert Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101278199
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
pubmed:
29
3
2020
medline:
14
4
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Celiac Disease (CD) is an autoimmune enteropathy caused by exposure to gluten in genetically predisposed people. While gluten is the main driving force in CD, evidence has shown that microbiota might be involved in the pathogenesis, development, and clinical presentation of CD. Microbiota manipulation may modify its functional capacity and may be crucial for setting-up potential preventive or therapeutic application. Moreover, probiotics are an excellent source of endopeptidases for digesting gluten. In this narrative review we illustrate all the recent scientific discoveries in this field including CD pathogenetic mechanism where gut microbiota might be involved and possible use of probiotics in CD prevention and treatment. In the future, probiotics could be used as an add-on medication for strengthening/facilitating the gluten-free diet (GFD) and improving symptoms; the prospect of using it for therapeutic purposes is to be sought in a more distant future.
Identifiants
pubmed: 32216476
doi: 10.1080/17474124.2020.1745630
doi:
Substances chimiques
Glutens
8002-80-0
Endopeptidases
EC 3.4.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM